Cadrenal Therapeutics, Inc. financial data

Symbol
CVKD on Nasdaq
Location
822 A1 A North, Suite 306, Ponte Vedra, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 384 % -52.8%
Debt-to-equity 35.1 % +152%
Return On Equity -265 % -183%
Return On Assets -196 % -139%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.05M shares -87.2%
Common Stock, Shares, Outstanding 2.01M shares -87.5%
Entity Public Float 4.01M USD -37.4%
Common Stock, Value, Issued 2.01K USD -87.5%
Weighted Average Number of Shares Outstanding, Basic 1.96M shares +83.8%
Weighted Average Number of Shares Outstanding, Diluted 1.96M shares +83.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.07M USD +104%
General and Administrative Expense 9.33M USD +125%
Operating Income (Loss) -14.4M USD -117%
Nonoperating Income (Expense) 293K USD -25.3%
Net Income (Loss) Attributable to Parent -14.1M USD -126%
Earnings Per Share, Basic -8 USD/shares +29%
Earnings Per Share, Diluted -8 USD/shares +29%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.57M USD +10.6%
Assets, Current 5.97M USD +9.71%
Property, Plant and Equipment, Net 4.28K USD +251%
Operating Lease, Right-of-Use Asset 2.2K USD -91.8%
Other Assets, Noncurrent 2.17K USD -42.9%
Assets 5.98M USD +9.55%
Accounts Payable, Current 896K USD +17.9%
Employee-related Liabilities, Current 967K USD +62.1%
Accrued Liabilities, Current 784K USD +12.5%
Liabilities, Current 1.68M USD +14.6%
Operating Lease, Liability, Noncurrent 2.23K USD
Liabilities 1.68M USD +14.6%
Retained Earnings (Accumulated Deficit) -33.2M USD -73.8%
Stockholders' Equity Attributable to Parent 4.3M USD +7.68%
Liabilities and Equity 5.98M USD +9.55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.65M USD -153%
Net Cash Provided by (Used in) Financing Activities 1.97M USD
Net Cash Provided by (Used in) Investing Activities -3.25K USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 2.01M shares -87.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.57M USD +10.6%
Deferred Tax Assets, Valuation Allowance 4.74M USD +118%
Deferred Tax Assets, Gross 4.74M USD +117%
Operating Lease, Liability 2.23K USD -91.8%
Depreciation 6.73K USD +198%
Payments to Acquire Property, Plant, and Equipment 3.25K USD
Lessee, Operating Lease, Liability, to be Paid 8.88K USD -0.59%
Operating Lease, Liability, Current 2.23K USD -91.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 22.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 22.7K USD +1.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 132 USD -94.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 22.3K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.75M USD +150%
Preferred Stock, Shares Authorized 7.5M shares 0%
Additional Paid in Capital 37.5M USD
Preferred Stock, Shares Outstanding 7.5M shares
Deferred Tax Assets, Net of Valuation Allowance 2.56M USD
Share-based Payment Arrangement, Expense 2.2M USD +260%
Interest Expense 41.6K USD +69.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%